Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
McKesson
Merck
Boehringer Ingelheim

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR HALOPERIDOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Haloperidol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000179 ↗ Agitation in Alzheimer's Disease Completed National Institute on Aging (NIA) Phase 3 1969-12-31 Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
NCT00000274 ↗ Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Completed New York State Psychiatric Institute Phase 2 1997-03-01 The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000274 ↗ Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-03-01 The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Haloperidol

Condition Name

Condition Name for Haloperidol
Intervention Trials
Schizophrenia 70
Delirium 34
Schizoaffective Disorder 13
Agitation 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Haloperidol
Intervention Trials
Schizophrenia 77
Delirium 49
Psychotic Disorders 32
Psychomotor Agitation 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Haloperidol

Trials by Country

Trials by Country for Haloperidol
Location Trials
United States 238
Netherlands 17
Spain 17
China 16
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Haloperidol
Location Trials
Texas 19
New York 18
California 15
Ohio 13
Pennsylvania 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Haloperidol

Clinical Trial Phase

Clinical Trial Phase for Haloperidol
Clinical Trial Phase Trials
Phase 4 75
Phase 3 46
Phase 2/Phase 3 7
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Haloperidol
Clinical Trial Phase Trials
Completed 137
Terminated 28
Unknown status 18
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Haloperidol

Sponsor Name

Sponsor Name for Haloperidol
Sponsor Trials
National Institute of Mental Health (NIMH) 7
National Cancer Institute (NCI) 6
Merck Sharp & Dohme Corp. 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Haloperidol
Sponsor Trials
Other 322
Industry 60
NIH 24
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Baxter
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.